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Abstract
We report onset, course, correlations with comorbidities, and diagnostic accuracy of naso-
pharyngeal swab in 539 individuals suspected to carry SARS-COV-2 admitted to the hospi-
tal of Crema, Italy. All individuals underwent clinical and laboratory exams, SARS-COV-2
reverse transcriptase-polymerase chain reaction on nasopharyngeal swab, and chest X-ray
and/or computed tomography (CT). Data on onset, course, comorbidities, number of drugs
including angiotensin converting enzyme (ACE) inhibitors and angiotensin-II-receptor
antagonists (sartans), follow-up swab, pharmacological treatments, non-invasive respira-
tory support, ICU admission, and deaths were recorded. Among 411 SARS-COV-2 patients
(67.7% males) median age was 70.8 years (range 5–99). Chest CT was performed in 317
(77.2%) and showed interstitial pneumonia in 304 (96%). Fatality rate was 17.5% (74%
males), with 6.6% in 60–69 years old, 21.1% in 70–79 years old, 38.8% in 80–89 years old,
and 83.3% above 90 years. No death occurred below 60 years. Non-invasive respiratory
support rate was 27.2% and ICU admission 6.8%. Charlson comorbidity index and high C-
reactive protein at admission were significantly associated with death. Use of ACE inhibitors
or sartans was not associated with outcomes. Among 128 swab negative patients at admis-
sion (63.3% males) median age was 67.7 years (range 1–98). Chest CT was performed in
87 (68%) and showed interstitial pneumonia in 76 (87.3%). Follow-up swab turned positive
in 13 of 32 patients. Using chest CT at admission as gold standard on the entire study
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population of 539 patients, nasopharyngeal swab had 80% accuracy. Comorbidity network
analysis revealed a more homogenous distribution 60–40 aged SARS-COV-2 patients
across diseases and a crucial different interplay of diseases in the networks of deceased
and survived patients. SARS-CoV-2 caused high mortality among patients older than 60
years and correlated with pre-existing multiorgan impairment.
Introduction
Since December 2019 outbreak in China of the novel coronavirus infection, designated SARS-
CoV-2 and termed Covid-19, the disease has quickly overflowed worldwide SARS-CoV-2
causes a clinical syndrome encompassing asymptomatic or oligosymptomatic flu-like course,
gastrointestinal disturbances, mild pneumonia, acute respiratory distress and death [1–6].
After the first Italian patient was notified on February 18th, 2020 at the hospital of Codogno,
25 km far from Crema, the total number of SARS-CoV-2 patients exponentially increased in
the area. The municipality of Crema, with about 34,000 inhabitants, experienced a rapid over-
load of the healthcare structures due to a massive influx of suspected SARS-CoV-2 patients.
We sought to perform a systematic analysis of hospitalized SARS-CoV-2 patients soon after
the outbreak and outline possible correlations with comorbidities and drug intake. To this
aim, we investigated all consecutive individuals suspected to harbor SARS-CoV-2 and admit-
ted to the General Hospital of Crema between February 21st and March 13rd, 2020 and fol-
lowed-up until March 19th, 2020. We provided data on onset, clinical history, laboratory and
radiological findings, course of the disease, age and sex-stratified fatality rate, and diagnostic
accuracy of the nasopharyngeal swab. The predictive power of not collinear variables was
investigated in death incidence, in the need of non-invasive ventilation/continuous positive
airway pressure and in the need of intensive unit care. We applied a network analysis [7, 8] to
assess the interactions between comorbidities across age groups and outcomes.
Materials and methods
On February 19th, 2020 the General and Health Directorate of the Hospital of Crema met to
update and carry out the available procedures to cope with the hospitalization of patients with
a potential viral spread, based on 2009 H1N1 pandemic strategic plan revised on December
2014 after Ebola outbreak. Starting on February 21st, 2020 the Emergency Department set up a
triage for any individual either reporting or presenting with fever (above 37.5˚C), cough or
dyspnea, or having had contact with SARS-CoV-2 carriers. All individuals admitted to the hos-
pital underwent body temperature and pulse oximetry (SO2) recording, hematological screen-
ing, chest X-ray and/or computed tomography (CT) and nasopharyngeal swab. Swabs were
stored at +4˚C and immediately shipped to one of the laboratory of virology accredited by the
Lombardy Region for diagnostic SARS-COV-2 real-time polymerase chain reaction assay.
Based on clinical, laboratory and radiological findings, patients were discharged to home in
quarantine or hospitalized.
Demographic data, date of onset and type of symptoms, comorbidities (e.g. hypertension,
cardiovascular disorders, diabetes, pulmonary diseases, active and previous malignancies,
renal insufficiency and any other known condition), current pharmacological treatments, use
of angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin-II-receptor
antagonists (sartans), and number of drugs were recorded. All available clinical data including
hematological and radiological exams, treatments, respiratory support with continuous
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positive airway pressure (CPAP) or non-invasive ventilation (NIV), intensive care unit (ICU)
admission and deaths were recorded. Chest X-ray and CT scan were scored as positive or neg-
ative based on radiologists’ written report. Acute reticular pattern at X-ray and the presence of
single or multiple ground-glass and/or consolidative lung opacities were considered indicative
of interstitial pneumonia (X-ray and CT positive). Pleural and pericardial effusion, and lymph-
adenopathy at CT scan were also recorded. For each patient the Charlson comorbidity index
was calculated [9].
The hospital of Crema is fully equipped with a computerized recording system that gener-
ates a unique code for any visit and exam. All patients were anonymized and locked to the
unique code assigned at the admission, and all data were included in an electronic database.
The Institutional Review Board of the Hospital of Crema has approved the study. All the exper-
iment protocol for involving human data was accordance to guidelines of national/interna-
tional/institutional or Declaration of Helsinki in the manuscript. Written informed consent
was obtained from all participants and legally authorized representatives of minors below 18
patients and dead patients gave consent for data that could be used for clinical studies.
Comorbidity network analysis
Two different sets of nodes were considered for the network analysis: 252 SARS-Cov-2 positive
patients and 13 possible diseases (cardiovascular disease (CaD), respiratory diseases (ReD),
diabetes, hypertension, renal insufficiency (ReI), cancer, arthritis, obesity, asthma, obstructive
sleep apneas (OSAS), dyslipidemia, chronic obstructive pulmonary disease COPD(), atrial
fibrillation (AF)) they could suffer for. A rectangular matrix patients (rows) vs diseases (col-
umns) (PvsD) was obtained by associating to the entry PvsD(i,j) one or zero according to the
fact that patient i had been suffering for the disease j or not. The information in this matrix
can be used to define an adjacency matrix [7] representing a graph, where two different sets of
nodes were included (patients and diseases) and for each non-zero entry of the matrix a link
between two nodes was included. The resulting graph is known as a bipartite network [10] that
is, a graph where nodes can be decomposed into two disjoint sets A and B such that edges con-
nect only elements of one set with elements of the other set. A common practice for bipartite
data mining is to find a projection of the whole graph over one of the two sets. The A-projec-
tion is composed of a network containing only A-nodes, where two A-nodes are connected
when they have at least N common neighboring B-node [10].
Comorbidity networks are typical bipartite where one set is given by the patients and the
other by their diseases [8]. In this study, it was obtained by firstly dividing the cohort of
patients in three classes of age: 40–60 years, 61–80 years, and 81–100 years. The networks have
been calculated as the projection of the patient-disease bipartite network on the diseases space.
This means that two diseases are connected by one edge if at least one patient suffer from both
and the weight of this edge is given by the total number of patients in this situation. Such final
monopartite disease networks have been filtered by fixing N to the 10% of the number of
patients included in each class. The three comorbidity networks have been analyzed in terms
of nodes weighted degree [7], that measures a node’s total level of involvement in the network,
and of modules detection [11] which iteratively optimizes local communities until global mod-
ularity can no longer be improved given perturbations to the current community state. There-
after, the same cohort has been divided in deceased and survived patients. Comorbidity
networks were obtained for the two groups in the same way described above and the same
topological analysis has been done. Before any projection, the columns of the PvsD matrix
were corrected for gender and age.
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In order to test the statistically significance of the difference between deceased and survived
networks, we decided to compare their normalized Laplacian matrices. The normalized Lapla-
cian matrix is a transformation of the adjacency matrix, whose eigenvalues describe aspects
related to the global network structure and dynamic interactions among network parts [12].
We derived, as reported in Supplementary Materials, the null model of the difference of the
two normalized Laplacian matrices and calculated the p-value associated.
Statistical analysis
Descriptive statistics were provided in terms of absolute number and percentage for categori-
cal data, and mean with standard deviation (SD) and median with interquartile range (IQR)
for continuous data. The predictive power of swabs outcome in CT scan classification (positive
or negative) has been tested by means of the receiver operating characteristic (ROC) curve
analysis [13] of a logistic regression [14]. Accordingly, the area under the curve of the ROC
curve was calculated. A multiple logistic regression analysis [15] to investigate the chances of
survival, the chances to need CPAP/NIV and the chances to need ICU as a function of few pre-
dictor variables was conducted. Such variables (Sex, Hypertension, Charlson comorbidity
index [9], Number of drugs assumed, White blood cells counts, Creatinine, C-reactive protein,
Alanine aminotransferase, Aspartate aminotransferase, positive X-Ray, positive CT scan, ACE
inhibitors and sartans consumption) were chosen among the others in order to exclude collin-
earities and to ensure that there was no violation of the linearity of the logit.
Comorbidity network has been analyzed by dividing the patients in three classes of age and
outcome (deceased and survived) at last day of follow-up. For each group, the comorbidity
network was derived according to the constraint that at least 10% of patients must share two
diseases.
Results
Clinical features of the study population
We collected data from 539 consecutive patients admitted to the hospital. All underwent naso-
pharyngeal swab, whose result was available within 24 hours on average. Overall, 411 patients
were swab positive and 128 negative. SARS-CoV-2 patients reported the onset of symptoms
for 5.3±4.3 days, whereas swab negative patients for 5.7±4.1 days. Table 1 reports the preva-
lence of the symptoms at onset.
Thirteen patients arrived in coma. Of them, 9 were SARS-CoV-2 patients and 5 died. The
other 4 patients were negative at nasopharyngeal swab; 3 died and 1 was hospitalized. Another
21 patients presented with disorientation and/or with psychomotor restlessness; 15 were
SARS-CoV-2 patients and 2 died. The other 6 patients were swab negative and 4 died. Notably,
41 (9.9%) SARS-CoV-2 patients reported or had at arrival one or more syncope; 14 of them
had a fall with trauma and 5 died. Another 6 (4.7%) swab negative patients reported syncope
and 1 died.
At admission, body temperature was slight above 37˚C both in SARS-CoV-2 and swab neg-
ative patients. Nevertheless, the large majority of patients reported the intake of paracetamol
during the previous hours, thus influencing the assessment at arrival. Similarly, the mean value
of pulse oximetry in patients who arrived in ambulance was influenced by the early treatment
with oxygen mask during transportation. The mean value of those who reached the hospital by
their own means did not differ between SARS-CoV-2 (93%, range 60–100) and swab negative
(92%, range 50–100) patients.
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Course and outcome in SARS-CoV-2 patients
Among 411 in SARS-CoV-2 patients at nasopharyngeal swab, the median age was 70.8 years
(range 5–99), with a preponderance of males (66.6%). Of 411 patients, 262 (63.7%) were hospi-
talized, 44 (10.7%) were transported to other regional hospitals, and 16 (3.9%) were discharged
to home in quarantine.
Chest X-ray was performed in 128 (31.1%) of 411 patients and was reported as suggestive of
interstitial pneumonia in 79 (61.7%) patients and negative in 49 (38.3%). Chest CT was per-
formed in 317 (77.2%) of 411 patients and showed interstitial pneumonia in 304 (96%),
whereas was negative in 13 (4%). It showed pleural effusion in 29 (9.1%) patients, lymphade-
nopathy in 37 (11.7%), and pericardial effusion in 27 (8.5%). Of the 38 (9.2%) patients who
underwent both the exams, 31 (81.6%) had concordant positive report, 6 (15.8%) had positive
CT scan and negative X-Ray report, and 1 (2.6%) had negative CT scan and positive X-Ray
report (Table 2).
Laboratory exams at admission showed white blood cell count below 10x109/L in 82% of
patients, neutrophil count below 10x109/L in 83.4%, and lymphocyte count below 1x109/L in
55.6%. C-reactive protein, aspartate aminotransferase and lactate dehydrogenase values were
elevated in most patients, particularly among those with worst clinical picture and outcome
(Table 3).
Six patients died within the first 72 hours and another 66 patients within two weeks after
hospitalization, giving an overall fatality rate of 17.5%. No death occurred in patients aged
below 60 years. In the older age groups, the number of deaths was 26 (88.5% males) in the
decade 70–79 and 31 (71% males) in the decade 80–89 (Fig 1). Non-invasive respiratory sup-
port was needed in 112 (27.2%) patients, with 28 (6.8%) requiring ICU admission.
Antiretroviral treatment with ritonavir plus lopinavir was started within the first 72 hours
in 42.3% of patients, in combination with hydroxychloroquine sulfate in 63% of them.
Table 1. Way of arrival at the hospital and symptoms reported by SARS-CoV-2 and swab negative patients.
n (%) Positive (411) Negative (128)
Arrival at hospital
Ambulance 196 (47.7) 36 (28.1)
Own means 215 (52.3) 92 (71.9)
Fever 346 (84.2) 97 (75.8)
Cough 151 (36.7) 44 (34.4)
Dyspnoea 131 (31.9) 34 (26.6)
Syncope 41 (9.9) 6 (4.7)
Fall with trauma 23 (5.6) 7 (5.4)
Nausea 18 (4.4) 5 (3.9)
Vomit 16 (3.9) 8 (3.7)
Diarrhoea 15 (3.6) 5 (3.9)
Confusion/psychomotor restlessness 15 (3.6) 6 (4.7)
Headache 10 (2.4) 2 (1.6)
Coma 9 (2.2) 4 (3.1)
Diffuse myalgia/arthralgia 7 (1.7) 2 (1.6)
Thoracic pain 7 (1.7) 10 (7.8)
Abdominal pain 5 (1.2) 2 (0.9)
Pharyngodinia 4 (1.0) 7 (5.4)
Recent pneumonia in treatment 4 (1.0) 3 (2.3)
https://doi.org/10.1371/journal.pone.0248498.t001
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Course, outcome and follow-up in nasopharyngeal swab negative patients
Among the 128 patients negative at nasopharyngeal swab, the median age was 67.7 years
(range 1–98), with a preponderance of males (63.3%). Seven patients (78 to 97 years) died.
Chest CT could be performed in 5 patients and it was positive in all. Of 128 patients, 82 (64%)
were hospitalized and 25 (19.5%) were discharged to home in quarantine. None was moved to
other regional hospitals.
Chest X-ray was performed in 59 (46%) of 128 patients and was reported as suggestive of
interstitial pneumonia in 30 (50.8%) and negative in 29 (49.2%). CT scan was performed in 87
(68%) of 128 patients and showed interstitial pneumonia in 76 (87.3%), whereas was negative
in 11 (12.7%). It showed pleural effusion in 6 (6.9%) patients, lymphadenopathy in 8 (9.2%),
and pericardial effusion in 41 (47.1%). Of the 21 (16.4%) patients who underwent both the
Table 2. Demographic and clinical characteristics in SARS-CoV-2 patients admitted to the Hospital of Crema between February 21st and March 13rd, 2020, and fol-
lowed up until March 19, 2020.
All patients (411) Deaths (72) ICU (28) CPAP/NIV (112)
Age
mean (standard deviation) 67.7 (15.0) 81.1 (7.5) 65.7 (12.1) 70.9 (10.9)
median (IQR) 70.8 (57.5–79.1) 80.7 (76.4–85.6) 69.1 (60.2–72.9) 72.2 (64.1–79.4)
Sex, n (%)
Male 278 (67.6) 53 (73.6) 26 (92.9) 91 (81.3)
Female 133 (32.4) 19 (26.4) 2 (7.1) 21 (18.7)
Cough, n (%) 151 (36.7) 8 (11.1) 11 (39.3) 33 (29.5)
Dyspnoea, n (%) 131 (31.9) 39 (54.2) 22 (78.6) 67 (59.8)
Any comorbidity, n (%) 256 (62.3) 61 (84.7) 23 (82.1) 87 (77.7)
Hypertension 193 (47.0) 48 (66.7) 20 (71.4) 67 (59.8)
Cardiovascular diseases 93 (22.6) 28 (38.9) 9 (32.1) 37 (33.0)
Diabetes 67 (16.3) 25 (34.7) 7 (25.0) 33 (29.5)
Pulmonary diseases 48 (11.7) 10 (13.9) 5 (17.9) 18 (16.1)
Renal insufficiency 22 (5.3) 11 (15.3) 5 (17.9) 11 (9.8)
Malignancies 33 (8.0) 9 (12.5) 2 (7.1) 8 (7.1)
Number of drugs, n (%)
0 124 (33.9) 10 (15.9) 4 (16.0) 19 (19.0)
<3 89 (24.3) 8 (12.7) 5 (20.0) 20 (20.0)
4–6 74 (20.2) 14 (22.2) 5 (20.0) 25 (25.0)
>7 79 (21.6) 31 (49.2) 11 (44.0) 36 (36.0)
ACE inhibitors, n (%) 50 (12.2) 11 (15.3) 4 (14.3) 20 (17.9)
Sartans, n (%) 60 (14.6) 14 (19.4) 9 (32.1) 22 (19.6)
X-Ray, n (%)
probable/possible 79 (61.7) 25 (34.7) 11 (39.3) 28 (25.0)
negative 49 (38.3) 3 (4.2) 1 (3.6) 4 (3.6)
not done 283 (68.9) 44 (61.1) 16 (57.1) 80 (71.4)
CT scan, n (%)
positive 304 (96.0) 50 (100) 23 (82.1) 92 (82.1)
negative 13 (4.0) 0 (0.0) 0 (0.0) 0 (0.0)
not done 94 (22.8) 22 (30.6) 5 (17.9) 20 (17.9)
X-ray and CT are intended as the first exam performed and percentage in brackets refers to the number of patients who have done the exams. Sums do not add up to the
total because of some missing values.
https://doi.org/10.1371/journal.pone.0248498.t002
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exams, 16 (76.2%) had concordant positive report, 3 (14.3%) had positive CT scan and nega-
tive X-Ray report, and 2 (9.5%) had concordant negative report.
Laboratory exams at admission showed white blood cell count below 10x109/L in 61% of
patients, neutrophil count below 10x109/L in 67.4%, and lymphocyte count below 1x109/L in
32.2%. C-reactive protein, aspartate aminotransferase and lactate dehydrogenase values were
mildly elevated in most patients, particularly those with worst clinical picture and outcome.
Two patients died within the first 72 hours and another 15 patients within two weeks after
hospitalization, giving an overall fatality rate of 13.3%. Nine (53%) of the 17 patients who died
had positive CT scan as compared to 25 (22.5%) in those hospitalized or discharged. Non-inva-
sive respiratory support was needed in 22 (17.2%) patients, with 4 (3.1%) requiring ICU
admission.
Table 3. Laboratory findings in SARS-CoV-2 patients admitted to the Hospital of Crema between February 21st and March 13rd, 2020, and followed up until March
19, 2020.
All patients (411) Deaths (72) ICU (28) CPAP/NIV (112)
White blood cell count, x 109 per L, n (%)
<4 56 (14.6) 3 (4.8) 0 (0.0) 5 (4.6)
4–10 281 (73.0) 43 (68.2) 20 (74.1) 77 (71.3)
>10 48 (12.5) 17 (27.0) 7 (25.9) 26 (24.1)
Neutrophil count, x 109 per L, n (%)
<7.5 321 (83.4) 41 (65.1) 16 (59.3) 71 (65.7)
>7.5 64 (16.6) 22 (34.9) 11 (40.7) 37 (34.3)
Lymphocyte count, x 109 per L, n (%)
<1 214 (55.6) 45 (71.4) 18 (66.7) 69 (63.9)
>1 171 (44.4) 18 (28.6) 9 (33.3) 39 (36.1)
C-reactive protein, mg/L, mean (SD) 7.51 (7.1) 13.2 (8.4) 15.8 (8.8) 12.9 (7.9)
median (IQR) 5.1 (2.7–11.5) 12.4 (6.4–18.1) 13.5 (10.5–21.4) 12.0 (6.5–18.0)
Creatinine, mg/dl
<1.3 283 (73.9) 29 (45.3) 14 (51.8) 70 (64.8)
>1.3 100 (26.1) 35 (54.7) 13 (48.2) 38 (35.2)
Alanine aminotransferase, U/L
<40 272 (71.8) 53 (76.8) 15 (55.6) 64 (54.3)
>40 107 (28.2) 16 (23.2) 12 (44.4) 44 (40.7)
Aspartate aminotransferase, U/L
<37 157 (40.5) 14 (20.3) 3 (11.1) 16 (14.7)
>37 231 (59.5) 55 (79.7) 24 (88.9) 93 (85.3)
Lactate dehydrogenase, U/L, mean (SD) 470 (839.3) 789 (1710) 988 (2064) 636 (1140)
median (IQR) 358 (265–498) 486 (373–596) 491 (356–581) 477 (362–586)
Creatine kinase, U/L, mean (SD) 401.5 (972.3) 650 (1660) 319 (256) 409 (1039)
median (IQR) 166 (86–395) 283 (163–301) 289 (125–362) 172 (85–461)
Arterial blood gas
pO2 partial pressure, mmHg, mean (SD) 69.7 (21.4) 64.4 (27.0) 59.2 (18.9) 61.2 (21.0)
median (IQR) 66.6 (58.2–76.3) 58.7 (50.3–66.7) 53.6 (44.2–67.2) 58.0 (49.6–67.4)
pCO2 partial pressure, mmHg, mean (SD) 33.9 (54.5) 33.7 (7.4) 33.7 (72.3) 33.8 (68.1)
median (IQR) 33.7 (30.8–36.3) 32.6 (28.9–36.5) 33.0 (30.6–37.0) 33.0 (29.9–35.9)
Lactate mmol/L, mean (SD) 1.2 (0.6) 1.7 (1.1) 1.4 (0.6) 1.5 (0.9)
median (IQR) 1.1 (0.8–1.4) 1.4 (1.0–2.0) 1.4 (1.0–1.7) 1.3 (1.0–1.7)
Sums do not add up to the total because of some missing values.
https://doi.org/10.1371/journal.pone.0248498.t003
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Antiretroviral treatment with ritonavir plus lopinavir was started in 27 (42.3%) patients, in
combination with hydroxychloroquine sulfate in 82.1% of them.
Of 128 patients, 32 (25%) repeated nasopharyngeal swab (median time 8 days, range 1–26);
13 (40.6%) patients turned positive and 8 of them had either X-ray or CT positive. None was
admitted to ICU and 3 died during hospitalization.
Diagnostic accuracy of nasopharyngeal swab
Because a number of patients had clinical and chest CT findings indicative of interstitial pneu-
monia, irrespective of the result of the nasopharyngeal swab, we calculated its diagnostic accu-
racy. To this aim, we used the report of chest CT as gold standard for the diagnosis of
interstitial pneumonia and calculated the diagnostic accuracy of the first nasopharyngeal swab
in entire study population of 539 patients. The sensitivity was 0.80 (CI 0.76–0.84) and the spec-
ificity was 0.45 (CI 0.25–0.65). A logistic regression was implemented to measure the predic-
tive power of swabs outcome in CT scan classification. The associated ROC curve was
calculated (Fig 2) and the AUC was 0.66.
Fig 1. Age and sex-stratification of the outcomes (CPAP/NIV, ICU admission, and death) in SARS-CoV-2 patients. Bars are numbers of patients.
Females are represented in the upper softer bars.
https://doi.org/10.1371/journal.pone.0248498.g001
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Comorbidity pattern and risk profile for outcome in SARS-CoV-2 patients
Charlson comorbidity index (p<0.001) and c-reactive protein (p<0.001) were significantly
associated with death (Table 4). Male gender (p<0.005), number of drugs intake (p<0.05),
white blood cells count (p<0.005), c-reactive protein (p<0.05), positive CT scan (p<0.05)
were significantly associated with the need of CPAP/NIV (Table 4), while only c-reactive pro-
tein (p<0.005) was associated with the need of IUC (Table 4).
Comorbidity network analysis was performed on the reduced set cohort of SARS-CoV-2
patients born between 1920 and 1980, and suffering for at least one of the diseases included in
the analysis. Subsequently, the reduced sample was divided in three age groups: 1920–1940,
1941–1960 and 1961–1980. The comorbidity networks obtained from those groups (Fig 3a–
3c) showed different topological properties. The community detection algorithm was able to
identify two modules for the age groups 1920–1940 and 1941–1960, whereas three communi-
ties characterized the age group 1961–1980. It means that in the older ranges of age there are
two different groups of diseases (violet and green in Fig 3a and pink and light green in Fig 3b)
Fig 2. Receiver operating characteristic curve analysis of the logistic regression that measured the predictive power of swabs outcome in CT
scan classification. AUC (area under the curve) estimates how a variable is far from the random predictive power (solid black line, AUC = 0.5).
https://doi.org/10.1371/journal.pone.0248498.g002
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and the number of patients who share two diseases is more similar between two nodes of the
same community than between two nodes of different communities. In both the age ranges
the main two nodes of the two communities are (hypertension, cardiac disease) and (diabetes
and respiratory disease) respectively. The pairs of communities are essentially the same in the
two networks apart COPD and OSAS that in the 1920–1940 age range network are associated
with the (hypertension, cardiac disease) community while in the 1941–1960 age range network
belong to the (diabetes and respiratory disease) community and cancer that in the 1920–1940
age range network is associated with the (hypertension, cardiac disease), while in the 1941–
Table 4. Estimated effects of selected predictors using multiple logistic regression model for three different outcomes (survival, requirement of continuous positive
airway pressure (CPAP)/non-invasive ventilation (NIV), intensive care unit (ICU) admittance) in SARS-CoV-2 patients admitted to the Hospital of Crema between
February 21st and March 13rd, 2020.
Chances of Survival Chances of CPAP/NIV requirement Chances of ICU admittance
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Intercept 9.70 (6.37–14.70) <0.001��� 0.32 (0.24–0.42) <0.001��� 0.02 (0.01–0.05) <0.001���
Sex 1.11 (0.78–1.56) 0.57 0.68 (0.51–0.90) <0.005�� 0.59 (0.28–1.23) 0.17
Hypertension 0.97 (0.68–1.39) 0.89 1.11 (0.83–1.47) 0.48 1.54 (0.89–2.67) 0.14
Charlson comorbidity index 0.34 (0.22–0.54) <0.001��� 1.24 (0.91–1.67) 0.19 0.58 (0.29–1.15) 0.13
Number of drugs 0.83 (0.60–1.14) 0.26 1.37 (1.02–1.81) <0.05� 1.49 (0.89–2.49) 0.14
White Blood Cells 0.83 (0.56–1.21) 0.3372 1.57 (1.16–2.13) <0.005�� 1.22 (0.85–1.75) 0.31
Creatinine 0.88 (0.65–1.19) 0.40 0.88 (0.68–1.16) 0.39 1.24 (0.77–1.98) 0.40
C-reactive protein 0.57 (0.41–0.78) <0.001��� 1.42 (1.09–1.85) <0.05� 1.99 (1.26–3.14) <0.005��
Alanine aminotransferase 1.10 (0.78–1.54) 0.60 1.17 (0.90–1.53) 0.28 1.01 (0.66–1.53) 0.95
Aspartate aminotransferase 0.87 (0.64–1.21) 0.43 1.19 (0.90–1.55) 0.21 1.37 (0.95–1.96) 0.10
X-Ray 0.77 (0.57–1.04) 0.10 1.20 (0.92–1.56) 0.19 1.32 (0.84–2.09) 0.25
CT scan 0.76 (0.49–1.18) 0.24 1.50 (1.07–2.12) <0.05� 1.58 (0.71–3.49) 0.27
ACE inhibitors 1.09 (0.79–1.51) 0.58 1.12 (0.88–1.44) 0.39 0.93 (0.57–1.53) 0.78
Sartans 1.04 (0.75–1.44) 0.80 1.07 (0.82–1.40) 0.61 0.88 (0.55–1.41) 0.61
We reported Odds ratio values (OR), 95% Confidence Interval (CI) and p-values (� p<0.05, �� p<0.005, ��� p<0.001).
https://doi.org/10.1371/journal.pone.0248498.t004
Fig 3. Comorbidity networks. A cohort of 270 Covid-19 patients was divided in three classes according to the year of birth: a) 1920–1940, b) 1941–
1960, c) 1961–1980. For each group a comorbidity network was derived according to the constraint that at least 10% of patients must share two diseases.
Nodes are ordered clockwise according to their degree (number of connection each disease has with other nodes), while node size is associated with the
number of patients sharing the disease. The color of each nodes refers to the community a disease belongs to.
https://doi.org/10.1371/journal.pone.0248498.g003
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1960 age range network belongs to the (diabetes and respiratory disease) community. Arthritis
and asthma appear only in the 1941–1960 age network, associated with the (hypertension, car-
diac disease) and the (diabetes and respiratory disease) communities respectively. Conversely,
the three communities configuration found in the 1961–1980 age group is associated with a
less homogeneous distribution of the number of patients who share diseases across the whole
network. In fact, we found one community composed of obesity and dyslipidemia, one com-
munity was composed of hypertension diabetes, asthma COPD and renal insufficiency, while
the last community was composed of CaD, ReD, OSAS, cancer and AF. The different weighted
degree (i.e. the node size in Fig 3) highlights a bimodal disease distribution among patients of
the two older age ranges. Specifically, hypertension, CaD and ReD seem to be more largely
present among patients, along with diabetes and chronic ReI in the 1920–1940 group, diabetes,
OSAS and COPD in the 1941–1960 group. In the 1961–1980 networks edge weights seem to
be similar among diseases. Finally, the same set of patients included in the analysis was divided
in two groups according to the outcome deceased or survived. Notably, two modules charac-
terized both the deceased and the survived network. The weighted degree distribution showed
that in one module deceased patients shared mainly hypertension, CaD, COPD and OSAS,
while in the other module ReD, ReI, diabetes dyslipidemia and cancer (Fig 4a). At the same
time, survived patients show one module mainly composed of hypertension and CaD, while in
the other one they shared mainly diabetes, ReD and COPD (Fig 5a). Figs 4b and 5b show the
Charlson comorbidity index distribution in the deceased and survived groups respectively,
highlighting the incidence of the diseases across subjects. Fig 6 shows the test of the statistically
significant difference between normalized Laplacian of survived and deceased networks. The
randomization approach allowed the rejection of the null hypothesis (the two graphs have the
same structure) with p< 0.007.
Fig 4. Comorbidity network of deceased patients. a) The comorbidity network was obtained according to patients outcome (deceased/survived). It
was derived according to the constraint that at least 10% of patients must share two diseases. Nodes are ordered clockwise according to their degree
(number of connection each disease has with other nodes), while node size is associated with the number of patients sharing the disease. The color of
each nodes refers to the community a disease belongs to; b) Pie chart of the Charlson Comorbidity Index calculated for each diseased patient. The
frequency of patients associated with a specific value of the index is reported within the brackets.
https://doi.org/10.1371/journal.pone.0248498.g004
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Randomization of a Laplacian matrix
Given a graph G(E,V), with M edges and N vertices, described by the NxN adjacency matrix
A, it is always possible to obtain its Laplacian as L = D–A, where D is a matrix with the degree
of the nodes on the diagonal and zeros elsewhere. L is, by construction, a semidefinite positive
matrix, that is a matrix whose eigen-spectrum is composed of non-negative terms. In order to
limit the eigen-spectrum in the interval [0,2], we calculated the normalized Laplacian matrix
as LN = D
-1/2(D-A)D-1/2. We randomized the normalized Laplacian matrix by using properties
of orthogonal matrices. Given a square matrix Q, it is orthogonal if its columns and rows are
orthogonal unit vectors [16]. One way to express this is QTQ = I, where QT is the transpose of
Q and I is the identity matrix. It can be showed that if P is a matrix with non-negative values
on the diagonal and zeros elsewhere, the matrix P’ = QPQT is symmetric and semidefinite pos-
itive, with eigenvalues given by the diagonal elements of P [16]. Accordingly, we created
N = 500000 random orthogonal matrices and calculated N replicas of survived and deceased
normalized Laplacian matrices. The null-distribution was obtained as the average difference of
each pair of replicas (survived and deceased), and the average difference between the empirical
survived and deceased normalized Laplacian matrices was tested against it.
Discussion and conclusions
We reported a systematic analysis on hospitalized SARS-CoV-2 patients soon after the out-
break in Italy. The strength of our study was the availability of homogenous data from all con-
secutive patients admitted to a public hospital and suspected to harbor SARS-CoV-2 infection.
Therefore, we could investigate the course of any patients presenting with symptoms indicative
of possible interstitial pneumonia, including those who resulted negative at nasopharyngeal
swab. One limitation is the report of the events occurring soon after the outbreak, during a
Fig 5. Comorbidity network of survived patients. a) The comorbidity network was obtained according to patients outcome (deceased/survived). It
was derived according to the constraint that at least 10% of patients must share two diseases. Nodes are ordered clockwise according to their degree
(number of connection each disease has with other nodes), while node size is associated with the number of patients sharing the disease. The color of
each nodes refers to the community a disease belongs to; b) Pie chart of the Charlson Comorbidity Index calculated for each survived patient. The
frequency of patients associated with a specific value of the index is reported within the brackets.
https://doi.org/10.1371/journal.pone.0248498.g005
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period in which many information on the disease course were not yet available, and with a
hospital-based perspective.
We examined 411 patients with laboratory-confirmed SARS-CoV-2 at nasopharyngeal
swab and compared their clinical features and course to that of 128 swab negative patients.
Overall, the percentage of SARS-CoV-2 patients that arrived at hospital with an ambulance
and required non-invasive respiratory support or ICU admittance was as twice as that of swab
negative patients. Nevertheless, the fatality rate was only about 4% higher in SARS-CoV-2
patients. At the same time, chest CT was reported as positive in nearly 60% of swab negative
Fig 6. Statistically significant difference between normalized Laplacian of deceased and survived networks. The difference resulted
significant with p<0.007. The grey distribution is the result of the difference between 500,000 randomization of survived and deceased
normalized Laplacian matrices. The red dot shows the difference between the original survived and deceased normalized Laplacian matrices.
The dotted vertical lines represent the 0.05 tails of the distribution. Original image created with the software Gelphi 0.9.1 https://gephi.org/.
https://doi.org/10.1371/journal.pone.0248498.g006
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patients, as previously reported [17], and mainly among those who died. These findings indi-
cate that a number of swab negative patients were admitted to the hospital because of an inter-
stitial pneumonia, which could be attributed to SARS-CoV-2 in 13 of the 32 patients in whom
it was possible to perform the follow-up nasopharyngeal swab that resulted positive. It has
been reported [18, 19] that RT-PCR on nasopharyngeal swab could be negative in patients
eventually receiving the diagnosis. Since nasopharyngeal swab is currently used as screening
tools in the population, its sensitivity value, namely the percentage of true positive, is impor-
tant. We sought to address this issue by using chest CT as the gold standard for the diagnosis
of interstitial pneumonia on the entire study population of 539 patients. In our cohort, we esti-
mated a sensitivity of 80%. This finding was similar to what found in other studies [20].
In our cohort, SARS-CoV-2 predominantly affected males. Our rate of 66.6% males con-
firmed those reported in China ranging between 54.3% and 73% [1–3, 21–24]. No biological
explanation for this unexpected gender distribution is currently available. Fatality rate related
to the whole population of SARS-CoV-2 subjects is unreliable and of limited usefulness in the
pandemic, while urgent strategies are needed to improve patients’ care and healthcare system
capability. Indeed, the number of SARS-CoV-2 subjects experiencing mild, or non-respiratory
symptoms (e.g. gastrointestinal), plus those asymptomatic are unknown because of the vari-
ability in testing policies. Since hospitalized patients carry the highest risk of dismal outcome,
the inherent fatality rate should be used also to compare findings across countries. Our hospi-
tal-based fatality rate in SARS-CoV-2 patients was 17.5%. Previous Chinese studies on hospi-
talized patients reported rates of 28% in 191 patients [22] and 21.8% in 201 patients [24].
Three studies including 99 [1], 41 [2] and 137 [25] patients reported lower rates ranging
between 11% [1, 25] and 14.6% [2]. Another two studies reported much lower rates of 1.4%
and 4.3% [3]. We did not record any death below 60 years. Mortality increased across the
decades and it was 6.6% in 60–69 years old, 21.1% in 70–79 years old, 38.8% in 80–89 years old
and 83.3% above 90 years. Nearly 74% of the deaths occurred in males, which may be not sur-
prising based on the predominantly male distribution of the diseases. Nevertheless, the fatality
rate among males exceeded by 10% that of the whole population of SARS-CoV-2 patients, sug-
gesting that the disease could more severely affect males. A similar difference between deaths
and infected was reported in one [22] out of three previous studies [23, 24]. Nonetheless, our
results show that the best proxies to predict adverse outcomes resulted to be the Charlson
comorbidity index and amount of c-reactive protein, suggesting that the fatality rate strongly
depend on the co-occurrence of several pathologies together with a high level of inflammation,
especially due to pulmonary infection diseases [26, 27].
Non-invasive respiratory support was needed in 27% of SARS-CoV-2 patients and ICU
admission rate was 6.8%. Previous Chinese studies [1–3, 25] reported ICU admission rates
between 4.3% and 31.7%, with fatality rate between 11% and 14.6%. A recent Italian study
focused on ICU patients [28] reported overall fatality rate of 26%. This comparison may sug-
gest that a larger availability of ICU beds might be associated with lower fatality rates. To inves-
tigate this hypothesis, we analyzed the distribution of the fatality rates in the decades 60–69 (76
patients) and 70–79 (123 patients) (Fig 1). The proportion of patients in CPAP/NIV and ICU
(32.9% and 6.5% in 60–69, respectively and 36.5% and 8.1% in 70–79, respectively) did not dif-
fer. Nevertheless, the fatality rate was 30% higher in the 70–79 (47%; 21/45; p = 0.02) than 60–
69 decade (16%; 4/25). Among patients admitted to ICU, the fatality rate was 40% (4/10) in the
70–79 years old, the same finding reported in the Italian larger series [28].
Tentative explanation of this difference could be the generic higher risk related to aging,
because patients in the two groups of age seemed to not significantly differ in terms of distribu-
tion of comorbidities and use of more than 4 drug (10% and 5% higher in 70–79 years old,
respectively). Thus, even though it might be possible that higher ICU admission rate could
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have reduced the mortality in the older age group, leading to a lower overall fatality rate, older
age per se might also play a major role on dismal outcome. Our statistical results show also
that if the best proxy to predict ICU admittance is the amount of c-reactive protein as already
showed by Sharifpour et al. [29], CPAP/NIV requirement is positively associated mainly with
male gender and white blood cells counts, as reported also by Krause at al. [30].
Besides this descriptive and multivariate statistical findings, particularly important results
have been obtained through the investigation of comorbidity patterns showed by patients strati-
fied according to the age and to the final outcome. All previous studies [1–3, 21–25, 31, 32]
reported high frequency of comorbidities mainly among patients with poorer outcome, suggest-
ing a role in enhancing SARS-CoV-2 morbidity [33]. To better correlate relationship and fre-
quency of comorbidities to age and outcome, we adopted a network analysis approach. Our
findings showed that the composition of the two communities found in in deceased and sur-
vived patients is crucial to discriminate the potential adverse outcome. In fact, while in both the
networks the main nodes of a community are (HT, CaD, COPD) in deceased patients and (HT,
CaD,ReI) in survived patients, in the other community we found (Red, ReI, diabetetes) for
deceased patients and (ReD,COPD,diabetes) for those who survived. As a consequence, the
major co-occurrence of respiratory disease and renal insufficiency seems to be a boost for an
adverse outcome, more than the HT and CaD co-occurrence. Moreover, an inhomogeneous dis-
tribution of the overall diseases co-occurrence was found in the age groups between 40 and 60
years, suggesting that a more diversified comorbidity can unlikely lead to a potential adverse
outcome. Even though indirectly and in a relatively small sample size, these findings seem sug-
gesting that SARS-CoV-2 morbidity is enhanced, and possibly even triggered by pre-existing
multi-organ impairment. These findings should be confirmed in a larger and multicenter study.
Finally, a major concern was raised on the use ACE inhibitors and sartans because SARS-
CoV-2 uses the ACE2 (angiotensin-converting enzyme 2) protein as the receptor to entry the
cells [34]. Our results confirmed that these classes of drug did not have any influence on
patients’ outcome [35, 36].
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